ATE282428T1 - Pharmazeutische dosierungsform von amorphem nilfenavir mesylat - Google Patents
Pharmazeutische dosierungsform von amorphem nilfenavir mesylatInfo
- Publication number
- ATE282428T1 ATE282428T1 AT02748680T AT02748680T ATE282428T1 AT E282428 T1 ATE282428 T1 AT E282428T1 AT 02748680 T AT02748680 T AT 02748680T AT 02748680 T AT02748680 T AT 02748680T AT E282428 T1 ATE282428 T1 AT E282428T1
- Authority
- AT
- Austria
- Prior art keywords
- nilfenavir
- amorphic
- mesylate
- dosage form
- pharmaceutical dosage
- Prior art date
Links
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 title 1
- 239000002552 dosage form Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28841001P | 2001-05-03 | 2001-05-03 | |
| PCT/EP2002/004711 WO2002089835A2 (en) | 2001-05-03 | 2002-04-29 | Pharmaceutical dosage form of amorphous nelfinavir mesylate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE282428T1 true ATE282428T1 (de) | 2004-12-15 |
Family
ID=23106974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02748680T ATE282428T1 (de) | 2001-05-03 | 2002-04-29 | Pharmazeutische dosierungsform von amorphem nilfenavir mesylat |
Country Status (37)
| Country | Link |
|---|---|
| US (1) | US7014866B2 (de) |
| EP (1) | EP1390063B1 (de) |
| JP (1) | JP4101661B2 (de) |
| KR (1) | KR100554816B1 (de) |
| CN (1) | CN1255185C (de) |
| AR (1) | AR034320A1 (de) |
| AT (1) | ATE282428T1 (de) |
| BG (1) | BG108311A (de) |
| BR (1) | BR0209325A (de) |
| CA (1) | CA2444116C (de) |
| CZ (1) | CZ20033211A3 (de) |
| DE (1) | DE60201988T2 (de) |
| EA (1) | EA006627B1 (de) |
| EC (1) | ECSP034827A (de) |
| ES (1) | ES2231717T3 (de) |
| GE (1) | GEP20053466B (de) |
| GT (1) | GT200200079A (de) |
| HK (1) | HK1070285A1 (de) |
| HR (1) | HRP20030873B1 (de) |
| HU (1) | HU229938B1 (de) |
| IL (2) | IL158306A0 (de) |
| IS (1) | IS7010A (de) |
| JO (1) | JO2401B1 (de) |
| MA (1) | MA27018A1 (de) |
| MX (1) | MXPA03009971A (de) |
| MY (1) | MY128509A (de) |
| NO (1) | NO20034689D0 (de) |
| NZ (1) | NZ528689A (de) |
| PA (1) | PA8544501A1 (de) |
| PE (1) | PE20021159A1 (de) |
| PL (1) | PL366998A1 (de) |
| PT (1) | PT1390063E (de) |
| RS (1) | RS83503A (de) |
| SK (1) | SK14572003A3 (de) |
| TW (1) | TWI234461B (de) |
| UA (1) | UA76463C2 (de) |
| WO (1) | WO2002089835A2 (de) |
Families Citing this family (112)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001034119A2 (en) | 1999-11-12 | 2001-05-17 | Abbott Laboratories | Inhibitors of crystallization in a solid dispersion |
| DE10026698A1 (de) | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
| CA2398226A1 (en) * | 2002-01-28 | 2003-07-28 | Pfizer Inc. | Increased-dosage nelfinavir tablet and method of making same |
| WO2005004868A1 (ja) | 2003-07-15 | 2005-01-20 | Arigen, Inc. | 抗コロナウイルス剤 |
| US8025899B2 (en) * | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| US8377952B2 (en) * | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
| BRPI0418330A (pt) * | 2003-12-31 | 2007-05-02 | Pfizer Prod Inc | composições sólidas de drogas de solubilidade baixa e poloxámeros |
| KR101351059B1 (ko) * | 2004-12-03 | 2014-02-17 | 머크 샤프 앤드 돔 코포레이션 | 방출 속도 조절용 조성물을 포함하는 카복스아미드 ｈｉｖ 인테그라제 억제제의 약제학적 제형 |
| DE602006011485D1 (de) * | 2005-09-23 | 2010-02-11 | Hoffmann La Roche | Neue dosierformulierung |
| PL1962808T3 (pl) * | 2005-12-14 | 2011-03-31 | Hoffmann La Roche | Preparat proleku przeciw HCV |
| ES2350497T3 (es) * | 2005-12-14 | 2011-01-24 | F. Hoffmann-La Roche Ag | Formulación de profármacos para el vhc. |
| AU2007283196A1 (en) * | 2006-08-10 | 2008-02-14 | Cipla Limited | Antiretroviral solid oral composition |
| PL2054040T3 (pl) | 2006-08-16 | 2011-09-30 | Novartis Ag | Sposób wytwarzania stałych dyspersji midostauryny |
| WO2008067164A2 (en) * | 2006-11-15 | 2008-06-05 | Abbott Laboratories | Solid pharmaceutical dosage formulations |
| CA2681628C (en) | 2007-03-16 | 2016-10-18 | Concert Pharmaceuticals, Inc. | Inhibitors of cholesterol ester transfer protein |
| US7528131B2 (en) * | 2007-04-19 | 2009-05-05 | Concert Pharmaceuticals Inc. | Substituted morpholinyl compounds |
| EP2152689B1 (de) | 2007-04-25 | 2013-01-02 | Concert Pharmaceuticals Inc. | Analoga von cilostazol |
| US8567657B2 (en) * | 2007-04-30 | 2013-10-29 | Mtj Consulting Services Inc. | Coiled tubing with retainer for conduit |
| US9194512B2 (en) | 2007-04-30 | 2015-11-24 | Mark Andreychuk | Coiled tubing with heat resistant conduit |
| DK3825306T3 (da) | 2007-05-01 | 2023-09-11 | Sun Pharmaceutical Ind Inc | Morphinanforbindelser |
| EP4183787A1 (de) | 2007-05-01 | 2023-05-24 | Concert Pharmaceuticals Inc. | Morphinanverbindungen |
| AU2008247805A1 (en) | 2007-05-01 | 2008-11-13 | Concert Pharmaceuticals Inc. | Naphthyl(ethyl) acetamides |
| MX370608B (es) | 2007-05-01 | 2019-12-18 | Concert Pharmaceuticals Inc | Compuestos de morfinano. |
| MX2009013565A (es) | 2007-06-12 | 2010-06-02 | Concert Pharmaceuticals Inc | Derivados de azapeptidos. |
| WO2009051782A1 (en) * | 2007-10-18 | 2009-04-23 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
| MX2010004222A (es) * | 2007-10-19 | 2010-09-14 | Purdue Research Foundation | Formulaciones solidas de compuestos cristalinos. |
| ITMI20080227A1 (it) * | 2008-02-13 | 2009-08-14 | Felice Vinati | '' dispositivo di sicurezza per apparati di sollevamento a fune '' |
| CA2716788C (en) | 2008-02-29 | 2016-08-16 | Concert Pharmaceuticals, Inc. | Deuterium-substituted xanthine derivatives |
| WO2009146310A1 (en) * | 2008-05-28 | 2009-12-03 | Concert Pharmaceuticals Inc. | Deuterated tizanidine |
| WO2010019557A1 (en) * | 2008-08-12 | 2010-02-18 | Concert Pharmaceuticals Inc. | N-phenyl-2-pyrimidineamine derivatives |
| EP2805950B1 (de) | 2008-09-19 | 2017-11-08 | Concert Pharmaceuticals, Inc. | Deuterierte Morphinanverbindungen |
| US20120053169A1 (en) | 2008-10-30 | 2012-03-01 | Amanda Thomas | Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury |
| WO2010062692A1 (en) | 2008-10-30 | 2010-06-03 | Concert Pharmaceuticals Inc. | Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury |
| CN103396473A (zh) | 2008-11-04 | 2013-11-20 | 安科治疗公司 | Cxcr4受体化合物 |
| US20110313004A1 (en) | 2008-12-04 | 2011-12-22 | Concert Pharmaceuticals, Inc. | Deuterated pyridinones |
| US20110053961A1 (en) | 2009-02-27 | 2011-03-03 | Concert Pharmaceuticals, Inc. | Substituted xanthine derivatives |
| BRPI1009199A2 (pt) | 2009-03-17 | 2016-03-08 | Concert Pharmaceuticals Inc | compostos de pirazinoisoquinolina |
| US20120244122A1 (en) | 2009-05-28 | 2012-09-27 | Masse Craig E | Peptides for the Treatment of HCV Infections |
| WO2011005520A1 (en) | 2009-06-23 | 2011-01-13 | Concert Pharmaceuticals, Inc. | Deuterium-modified triazolo-pyridazine derivatives as gaba-a receptor modulators |
| US20110015154A1 (en) * | 2009-07-20 | 2011-01-20 | Kellermann Gottfried H | Supporting acetylcholine function |
| WO2011047315A1 (en) | 2009-10-15 | 2011-04-21 | Concert Pharmaceuticals, Inc. | Subsitituted benzimidazoles |
| US20110098265A1 (en) * | 2009-10-28 | 2011-04-28 | Neuroscience, Inc. | Methods for reducing cravings and impulses associated with addictive and compulsive behaviors |
| WO2011060216A1 (en) | 2009-11-12 | 2011-05-19 | Concert Pharmaceuticals Inc. | Substituted azaindoles |
| WO2011103457A1 (en) | 2010-02-18 | 2011-08-25 | Concert Pharmaceuticals Inc. | Pyrimidine derivatives |
| EP2566494B1 (de) | 2010-02-26 | 2017-11-29 | Acer Therapeutics, Inc. | Cxcr4-rezeptorverbindungen |
| WO2011109464A1 (en) | 2010-03-02 | 2011-09-09 | Concert Pharmaceuticals Inc. | Deuterated tetrahydronaphthalene derivatives |
| US8575361B2 (en) | 2010-03-02 | 2013-11-05 | Concert Pharmaceuticals Inc. | Tetrahydronaphthalene derivatives |
| PL2579859T3 (pl) | 2010-06-14 | 2015-12-31 | Ratiopharm Gmbh | Kompozycja stała zawierająca iwabradynę |
| EP2616467A1 (de) | 2010-09-13 | 2013-07-24 | Concert Pharmaceuticals Inc. | Substituierte azaindole |
| EP2455068A1 (de) * | 2010-11-09 | 2012-05-23 | F. Hoffmann-La Roche AG | Pharmazeutische Zusammensetzung zur Behandlung von HCV-Infektionen |
| WO2012065028A2 (en) | 2010-11-11 | 2012-05-18 | Concert Pharmaceuticals Inc. | Substituted tetracyclines |
| WO2012079075A1 (en) | 2010-12-10 | 2012-06-14 | Concert Pharmaceuticals, Inc. | Deuterated phthalimide derivatives |
| US8447329B2 (en) | 2011-02-08 | 2013-05-21 | Longsand Limited | Method for spatially-accurate location of a device using audio-visual information |
| JP2014506603A (ja) | 2011-02-25 | 2014-03-17 | コンサート ファーマシューティカルズ インコーポレイテッド | ２−アミノ−ナフチリジン誘導体 |
| WO2012129381A1 (en) | 2011-03-22 | 2012-09-27 | Concert Pharmaceuticals Inc. | Deuterated preladenant |
| US20140213553A1 (en) | 2011-05-03 | 2014-07-31 | Concert Pharmaceuticals Inc. | Carbamoylpyridone derivatives |
| WO2012154728A1 (en) | 2011-05-10 | 2012-11-15 | Concert Pharmaceuticals Inc. | Deuterated n-butyl bumetanide |
| DK2709986T3 (en) | 2011-05-18 | 2017-05-08 | Concert Pharmaceuticals Inc | DEUTERATED DERIVATIVES OF IVACAFTOR |
| WO2013013052A1 (en) | 2011-07-19 | 2013-01-24 | Concert Pharmaceuticals, Inc. | Substituted xanthine derivatives |
| FR2985177B1 (fr) * | 2012-01-02 | 2016-04-01 | Oreal | Composition cosmetique solide aqueuse comprenant de l'alkylcellulose, au moins deux huiles non volatiles et au moins deux agents tensioactifs |
| EP2802596A1 (de) | 2012-01-09 | 2014-11-19 | Anchor Therapeutics, Inc. | Apj-rezeptorverbindungen |
| WO2013130849A1 (en) | 2012-02-29 | 2013-09-06 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
| CN104364255A (zh) | 2012-04-13 | 2015-02-18 | 康塞特医药品有限公司 | 取代的黄嘌呤衍生物 |
| US9249093B2 (en) | 2012-04-20 | 2016-02-02 | Concert Pharmaceuticals, Inc. | Deuterated rigosertib |
| WO2013188783A1 (en) | 2012-06-15 | 2013-12-19 | Concert Pharmaceuticals, Inc. | Deuterated derivatives of ruxolitinib |
| ES2694202T3 (es) | 2012-07-12 | 2018-12-19 | Concert Pharmaceuticals, Inc. | Idebenona deuterada |
| EP2885303B1 (de) | 2012-08-17 | 2018-12-26 | CoNCERT Pharmaceuticals, Inc. | Deuteriertes baricitinib |
| WO2014078842A1 (en) | 2012-11-19 | 2014-05-22 | Concert Pharmaceuticals, Inc. | Deuterated cftr potentiators |
| MX2015008187A (es) | 2012-12-20 | 2016-02-05 | Concert Pharmaceuticals Inc | Inhibidores de alk deuterados. |
| EP2938343B1 (de) | 2012-12-21 | 2018-09-12 | Mayo Foundation For Medical Education And Research | Verfahren und materialien zur behandlung von kalkaortenklappenstenose |
| WO2014110322A2 (en) | 2013-01-11 | 2014-07-17 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
| WO2014150043A1 (en) | 2013-03-15 | 2014-09-25 | Concert Pharmaceuticals Inc. | Inhibitors of the enzyme udp-glucose: n-acyl-sphingosine glucosyltransferase |
| JP2016512831A (ja) | 2013-03-15 | 2016-05-09 | コンサート ファーマシューティカルズ インコーポレイテッド | 重水素化されたパルボシクリブ |
| HU231191B1 (hu) | 2013-04-15 | 2021-08-30 | Szegedi Tudományegyetem | Izotóp tartalmú morfin molekulák |
| WO2015010045A1 (en) | 2013-07-18 | 2015-01-22 | Anchor Therapeutics, Inc. | Apj receptor compounds |
| WO2015009889A1 (en) | 2013-07-18 | 2015-01-22 | Concert Pharmaceuticals, Inc. | Deuterated intedanib derivatives and their use for the treatment of proliferative disorders |
| WO2015031741A1 (en) | 2013-08-30 | 2015-03-05 | Concert Pharmaceuticals, Inc. | Deuterated derivatives of a thienotriazolodiazapine bromodomain-containing protein inhibitor |
| CN106459056A (zh) | 2014-02-10 | 2017-02-22 | 康塞特医药品公司 | 经取代的三唑苯二氮卓 |
| CN106456647A (zh) | 2014-04-18 | 2017-02-22 | 康塞特医药品有限公司 | 治疗高血糖症的方法 |
| WO2015179772A1 (en) | 2014-05-23 | 2015-11-26 | Concert Pharmaceuticals, Inc. | Deuterated phenylquinazolinone and phenylisoquinolinone compounds |
| EP3152200A1 (de) | 2014-06-06 | 2017-04-12 | Research Triangle Institute | Apelin-rezeptor (apj-) agonisten und ihre verwendung |
| WO2016022955A1 (en) | 2014-08-07 | 2016-02-11 | Mayo Foundation For Medical Education And Research | Compounds and methods for treating cancer |
| WO2016061488A1 (en) | 2014-10-17 | 2016-04-21 | Concert Pharmaceuticals, Inc. | Amine reuptake inhibitors |
| WO2016073545A1 (en) | 2014-11-06 | 2016-05-12 | Concert Pharmaceuticals, Inc. | Phenyloxadiazole benzoic acids |
| WO2016089814A1 (en) | 2014-12-02 | 2016-06-09 | Concert Pharmaceuticals, Inc. | Deuterated analogues of daclatasvir |
| US10301281B2 (en) | 2014-12-11 | 2019-05-28 | Merck Sharp & Dohme Corp. | Crystal forms of a CCR5 antagonist |
| CN105769809A (zh) * | 2014-12-23 | 2016-07-20 | 上海星泰医药科技有限公司 | 提高生物利用度的雷尼司他及其制备方法 |
| WO2016105547A1 (en) | 2014-12-24 | 2016-06-30 | Concert Pharmaceuticals, Inc. | Deuterated dasabuvir |
| WO2016109795A1 (en) | 2014-12-31 | 2016-07-07 | Concert Pharmaceuticals, Inc. | Deuterated funapide and difluorofunapide |
| EP3265440A1 (de) | 2015-03-06 | 2018-01-10 | Concert Pharmaceuticals Inc. | Deuteriertes emricasan |
| US10196384B2 (en) | 2015-03-31 | 2019-02-05 | Vertex Pharmaceuticals (Europe) Limited | Deuterated CFTR modulators |
| WO2016176335A1 (en) | 2015-04-27 | 2016-11-03 | Concert Pharmaceuticals, Inc. | Deuterated otx-015 |
| WO2017020005A1 (en) | 2015-07-30 | 2017-02-02 | Concert Pharmaceuticals, Inc. | Morphinan compounds for use in treating agitation |
| CA2994169A1 (en) | 2015-07-30 | 2017-02-02 | Concert Pharmaceuticals, Inc. | Deuterated morphinan compounds for use in treating agitation |
| BR112018005454A2 (pt) | 2015-09-21 | 2018-10-09 | Vertex Pharmaceuticals Europe Ltd | administração de potencializadores de cftr deuterados |
| US11267777B2 (en) | 2015-11-19 | 2022-03-08 | Concert Pharmaceuticals, Inc. | Deuterated EPI-743 |
| MX2018006979A (es) | 2015-12-09 | 2019-05-16 | Res Triangle Inst | Antagonistas del receptor de la apelina (apj) mejorados y usos de los mismos. |
| WO2017147003A1 (en) | 2016-02-26 | 2017-08-31 | Novobiotic Pharmaceuticals, Llc | Novel macrocyclic antibiotics and uses thereof |
| US10561659B2 (en) | 2016-05-04 | 2020-02-18 | Concert Pharmaceuticals, Inc. | Treatment of hair loss disorders with deuterated JAK inhibitors |
| EP4122919A1 (de) | 2016-07-04 | 2023-01-25 | Avanir Pharmaceuticals, Inc. | Verfahren zur synthese von deuteriertem dextromethorphan |
| JP7178341B2 (ja) | 2016-08-01 | 2022-11-25 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | タンパク質およびペプチドの送達のための粒子 |
| US10696677B2 (en) | 2016-12-21 | 2020-06-30 | Research Triangle Institute | Diaryl purine derivatives with improved bioavailability |
| CA3054572A1 (en) | 2017-02-28 | 2018-09-07 | Mayo Foundation For Medical Education And Research | Compounds and methods for treating cancer |
| WO2018213609A1 (en) | 2017-05-17 | 2018-11-22 | Ausubel Frederick M | Antibiotic compounds |
| DK3625231T3 (da) | 2017-05-19 | 2022-10-31 | Superb Wisdom Ltd | Derivatives of resiquimod |
| WO2019104179A1 (en) | 2017-11-22 | 2019-05-31 | Concert Pharmaceuticals, Inc. | Deuterated analogs of d-serine and uses thereof |
| US11243207B2 (en) | 2018-03-29 | 2022-02-08 | Mayo Foundation For Medical Education And Research | Assessing and treating cancer |
| WO2021236139A1 (en) | 2020-05-21 | 2021-11-25 | Concert Pharmaceuticals, Inc. | Novel deuterated jak inhibitor and uses thereof |
| PE20231945A1 (es) | 2020-10-28 | 2023-12-05 | Sun Pharmaceutical Ind Inc | Regimenes para el tratamiento de los trastornos de la perdida de cabello con inhibidores de jak deuterados |
| CN118159272A (zh) | 2021-08-11 | 2024-06-07 | 太阳医药工业公司 | 用氘化的jak抑制剂来治疗脱发病症 |
| CA3228509A1 (en) | 2021-08-12 | 2023-02-16 | Sun Pharmaceutical Industries, Inc. | Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors |
| WO2023215520A1 (en) | 2022-05-04 | 2023-11-09 | Sun Pharmaceutical Industries, Inc. | Dosage regimens for treatment with deuterated jak inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5281420A (en) * | 1992-05-19 | 1994-01-25 | The Procter & Gamble Company | Solid dispersion compositions of tebufelone |
| IE80467B1 (en) * | 1995-07-03 | 1998-07-29 | Elan Corp Plc | Controlled release formulations for poorly soluble drugs |
| US5834472A (en) * | 1996-05-24 | 1998-11-10 | Schering Corporation | Antifungal composition with enhanced bioavailability |
| US6232333B1 (en) * | 1996-11-21 | 2001-05-15 | Abbott Laboratories | Pharmaceutical composition |
| US6045829A (en) * | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
| US6001851A (en) * | 1997-03-13 | 1999-12-14 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
| AU729529B2 (en) * | 1997-06-06 | 2001-02-01 | Depomed, Inc. | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
| WO1998057648A1 (en) * | 1997-06-16 | 1998-12-23 | Vertex Pharmaceuticals Incorporated | Methods of increasing the bioavailability of stable crystal polymorphs of a compound |
| DE69828635T2 (de) * | 1997-09-19 | 2005-06-16 | Shire Laboratories, Inc. | Feste lösungskügelchen |
| MXPA02004739A (es) * | 1999-11-12 | 2003-01-28 | Abbott Lab | Formulaciones farmaceuticas de dispersion solida. |
| US6499984B1 (en) * | 2000-05-22 | 2002-12-31 | Warner-Lambert Company | Continuous production of pharmaceutical granulation |
-
2002
- 2002-04-29 MX MXPA03009971A patent/MXPA03009971A/es active IP Right Grant
- 2002-04-29 ES ES02748680T patent/ES2231717T3/es not_active Expired - Lifetime
- 2002-04-29 CZ CZ20033211A patent/CZ20033211A3/cs unknown
- 2002-04-29 RS YU83503A patent/RS83503A/sr unknown
- 2002-04-29 KR KR1020037014234A patent/KR100554816B1/ko not_active IP Right Cessation
- 2002-04-29 WO PCT/EP2002/004711 patent/WO2002089835A2/en active IP Right Grant
- 2002-04-29 PT PT02748680T patent/PT1390063E/pt unknown
- 2002-04-29 EA EA200301166A patent/EA006627B1/ru not_active IP Right Cessation
- 2002-04-29 AT AT02748680T patent/ATE282428T1/de active
- 2002-04-29 DE DE60201988T patent/DE60201988T2/de not_active Expired - Lifetime
- 2002-04-29 GE GE5295A patent/GEP20053466B/en unknown
- 2002-04-29 HU HU0401238A patent/HU229938B1/hu not_active IP Right Cessation
- 2002-04-29 JP JP2002586967A patent/JP4101661B2/ja not_active Expired - Fee Related
- 2002-04-29 BR BR0209325-1A patent/BR0209325A/pt not_active Application Discontinuation
- 2002-04-29 NZ NZ528689A patent/NZ528689A/en unknown
- 2002-04-29 CN CNB028092953A patent/CN1255185C/zh not_active Expired - Fee Related
- 2002-04-29 IL IL15830602A patent/IL158306A0/xx unknown
- 2002-04-29 EP EP02748680A patent/EP1390063B1/de not_active Expired - Lifetime
- 2002-04-29 PL PL02366998A patent/PL366998A1/xx unknown
- 2002-04-29 CA CA002444116A patent/CA2444116C/en not_active Expired - Fee Related
- 2002-04-29 UA UA20031210981A patent/UA76463C2/uk unknown
- 2002-04-29 SK SK1457-2003A patent/SK14572003A3/sk unknown
- 2002-04-30 MY MYPI20021591A patent/MY128509A/en unknown
- 2002-04-30 PE PE2002000369A patent/PE20021159A1/es not_active Application Discontinuation
- 2002-04-30 TW TW091108967A patent/TWI234461B/zh not_active IP Right Cessation
- 2002-04-30 PA PA20028544501A patent/PA8544501A1/es unknown
- 2002-04-30 AR ARP020101580A patent/AR034320A1/es not_active Application Discontinuation
- 2002-05-01 JO JO200237A patent/JO2401B1/en active
- 2002-05-02 US US10/138,071 patent/US7014866B2/en not_active Expired - Fee Related
- 2002-05-02 GT GT200200079A patent/GT200200079A/es unknown
-
2003
- 2003-10-08 IL IL158306A patent/IL158306A/en not_active IP Right Cessation
- 2003-10-20 NO NO20034689A patent/NO20034689D0/no not_active Application Discontinuation
- 2003-10-28 HR HR20030873A patent/HRP20030873B1/xx not_active IP Right Cessation
- 2003-10-30 IS IS7010A patent/IS7010A/is unknown
- 2003-10-31 EC EC2003004827A patent/ECSP034827A/es unknown
- 2003-11-03 MA MA27379A patent/MA27018A1/fr unknown
- 2003-11-03 BG BG108311A patent/BG108311A/bg unknown
-
2005
- 2005-04-11 HK HK05103024A patent/HK1070285A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE282428T1 (de) | Pharmazeutische dosierungsform von amorphem nilfenavir mesylat | |
| NO20030627L (no) | Hydrogel-drevet medikament doseringsform | |
| ATE307571T1 (de) | Pharmazeutische formulierung enthaltend bicalutamid | |
| NO20033384L (no) | Farmasoytisk formulering | |
| NO20022970D0 (no) | Hydrogel-drevet medikamentdoseringsform | |
| ATE395053T1 (de) | Pharmazeutische salze von 1-phenyl-3- dimethylamino-propan-verbindungen | |
| DE60201859D1 (de) | Pharmazeutische Verwendung von N-Carbamoylazol-Derivate | |
| DE60213592D1 (de) | Flüssige pharmazeutische zusammensetzung | |
| ATE317260T1 (de) | Pharmazeutische formulierungen mit platinderivaten | |
| ATE355271T1 (de) | Pharmazeutische zusammensetzung | |
| ATE320256T1 (de) | Succinate des 5,8,14-triazatetracyclo(10.3.1.0 2, 11 .0 4,9 )-hexadeca-2(11),3,5,7,9,-pentaens und pharmazeutische zusammensetzungen | |
| NO20035627D0 (no) | Farmasöytisk formulering | |
| DE60217390D1 (de) | Bicalutamid enthaltende pharmazeutische zusammensetzung | |
| ATE366128T1 (de) | Pharmazeutische zusammensetzung | |
| DE10291905D2 (de) | Pharmazeutische Zusammensetzung | |
| NO20033162D0 (no) | Farmasoytisk tablett omfattende paroksetinmesylat | |
| ATE350029T1 (de) | Pharmazeutische zusammensetzung enthaltend gamma- butyrobetain | |
| ATE439354T1 (de) | Pharmazeutische salze von reboxetin | |
| DE60214533D1 (de) | Pyridoindolonderivate und antikrebsmittel enthaltende pharmazeutische mischungen | |
| DE10107261B4 (de) | Pharmazeutische Zusammensetzung | |
| ATE349213T1 (de) | Nasale pharmazeutische zusammensetzung von piribedil | |
| EE200300563A (et) | Bensüülaminopürimidiiniühendid, nende kasutamine ja ravim | |
| NO20041236L (no) | Farmasoytisk formulering | |
| FI20011192A0 (fi) | Flavonoidilääkeaine ja annostusmuoto, sen valmistus ja käyttö | |
| DK1390063T3 (da) | Farmaceutisk doseringsform af amorft nelfinavir-mesylat |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1390063 Country of ref document: EP |